Testing a new immunotherapy with pembrolizumab for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests ABX-001, a new immunotherapy, alone or with pembrolizumab, for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. It may help if your tumor has become resistant to previous immunotherapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have an advanced solid tumor that has grown despite prior treatment or you cannot tolerate standard therapy.
- For part B, you must have received pembrolizumab before and your tumor either did not respond or stopped responding after initial improvement.
- You must be willing to have a tumor biopsy before starting and have another tumor that can be measured.
- You must be at least 18 years old and able to give consent.
- Your overall health should be good (ECOG performance status 0 or 1) and life expectancy at least 12 weeks.
- You must have adequate kidney, liver, and blood cell counts and no uncontrolled heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
This trial tests a new drug called PYX-201 combined with an immunotherapy (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors and help people live longer with manageable side effects.
This trial tests a new drug called APX-343A, either by itself or in combination with the immunotherapy pembrolizumab, for people with advanced solid tumors that have not responded to prior treatments.
This early-phase study tests a new treatment in people with advanced (locally advanced or metastatic) solid tumors that have worsened or cannot be treated with standard therapies. It may help shrink tumors or slow growth, and it also helps doctors learn the safest way to use the medicine.
This study tests a new drug called PLN-101095 in people with advanced solid tumors whose cancer has stopped responding to a common immunotherapy. The goal is to see if combining this new drug with pembrolizumab can help control the cancer again.
This trial tests a new drug called ABL103 combined with pembrolizumab (immunotherapy) and with or without a chemotherapy drug called taxane. It is for people with advanced or metastatic solid tumors that have stopped responding to standard treatments or cannot tolerate them.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.